PureTech Health PLC (PRTC)

London
287.50
-7.00(-2.38%)
  • Volume:
    13,026
  • Bid/Ask:
    287.50/288.50
  • Day's Range:
    287.50 - 297.00

PRTC Overview

Prev. Close
294.5
Day's Range
287.5-297
Revenue
12.82M
Open
297
52 wk Range
145.8-305
EPS
-0.047
Volume
13,026
Market Cap
807.37M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
559,161
P/E Ratio
-56.24
Beta
0.966
1-Year Change
5.37%
Shares Outstanding
278,452,556
Next Earnings Date
-
What is your sentiment on PureTech Health PLC?
or
Vote to see community's results!

PureTech Health PLC News

PureTech Health PLC Company Profile

PureTech Health PLC Company Profile

Employees
95

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer’s disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer’s and Parkinson’s diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Read More

Analyst Price Target

Average9.09 (-96.84% Downside)
High12.634
Low5.5515
Price287.5
No. of Analysts2
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellNeutralBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Buy
SummaryStrong SellStrong SellSellStrong BuyStrong Buy